CEACAM5 and breast cancer: In the 9 metastatic BC patients enrolled in an optimization immuno-PET study evaluating TF2 /68Ga-IMP288, with median CA15-3 was 249.3 kUI/L (40–2,448) and a median CEA of 76 μg/L (9.5–1359.0), pretargeted anti-CEA immuno-PET allowed the detection of a total of 533 lesions, whereas 245 lesions were detected by CT, 160 by bone MRI, and 425 by 18FDG-PET/CT (Figure 2).